Marktanalyse - Hidradenitis Suppurativa - Pipeline Review, H1 2017

Global Markets Direct
02.2017
92 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Hidradenitis Suppurativa - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa — Pipeline Review, H1 2017, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 4, 1, 8 and 1 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hidradenitis Suppurativa - Overview

Hidradenitis Suppurativa - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hidradenitis Suppurativa - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hidradenitis Suppurativa - Companies Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

Celgene Corp

Cell Medica Ltd

Cellceutix Corp

Coherus BioSciences Inc

InflaRx GmbH

NeuClone Pty Ltd

Novartis AG

Panacea Biotec Ltd

Sandoz International GmbH

XBiotech Inc

Hidradenitis Suppurativa - Drug Profiles

adalimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJM-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-2751 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MABp-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Hidradenitis Suppurativa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hidradenitis Suppurativa - Dormant Projects

Hidradenitis Suppurativa - Discontinued Products

Hidradenitis Suppurativa - Product Development Milestones

Featured News & Press Releases

Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa

Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa

Nov 14, 2016: AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease

Sep 26, 2016: AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress

Aug 03, 2016: Clinical trial results support adalimumab treatment for painful skin condition

May 09, 2016: Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland

May 04, 2016: NICE recommends Humira (adalimumab) as the first approved treatment for skin condition hidradenitis suppurativa in England and Wales

Mar 02, 2016: Abbvie Announces New Dermatology Research From More Than 35 Presentations On Humira (Adalimumab), Long-Term And Real-World Data At The American Academy Of Dermatology 2016 Annual Meeting

Jan 06, 2016: AbbVie HUMIRA (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa

Oct 05, 2015: AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress

Sep 10, 2015: Abbvie's Humira (Adalimumab) Receives First And Only U.S. Food And Drug Administration Approval For Moderate To Severe Hidradenitis Suppurativa

Jul 30, 2015: Humira (Adalimumab) Approved By European Commission For Moderate To Severe Hidradenitis Suppurativa

Jun 26, 2015: Abbvie's Humira (Adalimumab) Receives Positive Chmp Opinion To Treat Adult Patients With Active Moderate To Severe Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease

May 15, 2015: Abbvie Receives Orphan Drug Designation For Humira (Adalimumab) From The U.S. Food And Drug Administration For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa

Mar 17, 2015: Abbvie's Dermatology Leadership Showcased With Humira (Adalimumab) Data At American Academy Of Dermatology 2015 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Hidradenitis Suppurativa, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hidradenitis Suppurativa - Pipeline by AbbVie Inc, H1 2017

Hidradenitis Suppurativa - Pipeline by Amgen Inc, H1 2017

Hidradenitis Suppurativa - Pipeline by Celgene Corp, H1 2017

Hidradenitis Suppurativa - Pipeline by Cell Medica Ltd, H1 2017

Hidradenitis Suppurativa - Pipeline by Cellceutix Corp, H1 2017

Hidradenitis Suppurativa - Pipeline by Coherus BioSciences Inc, H1 2017

Hidradenitis Suppurativa - Pipeline by InflaRx GmbH, H1 2017

Hidradenitis Suppurativa - Pipeline by NeuClone Pty Ltd, H1 2017

Hidradenitis Suppurativa - Pipeline by Novartis AG, H1 2017

Hidradenitis Suppurativa - Pipeline by Panacea Biotec Ltd, H1 2017

Hidradenitis Suppurativa - Pipeline by Sandoz International GmbH, H1 2017

Hidradenitis Suppurativa - Pipeline by XBiotech Inc, H1 2017

Hidradenitis Suppurativa - Dormant Projects, H1 2017

Hidradenitis Suppurativa - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Hidradenitis Suppurativa, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus